ASTELLAS PHARMA UNSP.ADR Market Cap ($19.55 Billion)
Market Cap & Net Worth: ASTELLAS PHARMA UNSP.ADR (YPHA)
ASTELLAS PHARMA UNSP.ADR market cap. ASTELLAS PHARMA UNSP.ADR (F:YPHA) has a market capitalization of $19.55 Billion (€16.72 Billion) as of November 3, 2026. Listed on the F stock exchange, this Germany-based company holds position #1278 globally and #292 in its home market, demonstrating a -3.73% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ASTELLAS PHARMA UNSP.ADR's stock price €12.90 by its total outstanding shares 1791215714 (1.79 Billion). Also see how efficiently does ASTELLAS PHARMA UNSP.ADR generate cash for how efficiently the company converts equity into cash flow.
ASTELLAS PHARMA UNSP.ADR Market Cap History (2020–2026)
ASTELLAS PHARMA UNSP.ADR market cap history from 2020 to 2026. Data shows growth from $22.79 Billion to $29.74 Billion (0.06% CAGR). Check latest ASTELLAS PHARMA UNSP.ADR stock price today for real-time trading data and today's change.
ASTELLAS PHARMA UNSP.ADR Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ASTELLAS PHARMA UNSP.ADR's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of ASTELLAS PHARMA UNSP.ADR to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.01x
ASTELLAS PHARMA UNSP.ADR's market cap is 0.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.46x
ASTELLAS PHARMA UNSP.ADR's market cap is 0.46 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $27.87 Billion | $1.30 Trillion | $124.09 Billion | 0.02x | 0.22x |
| 2023 | $21.69 Billion | $1.52 Trillion | $98.71 Billion | 0.01x | 0.22x |
| 2024 | $18.85 Billion | $1.60 Trillion | $17.05 Billion | 0.01x | 1.11x |
| 2025 | $23.24 Billion | $1.91 Trillion | $50.75 Billion | 0.01x | 0.46x |
Competitor Companies of YPHA by Market Capitalization
Companies near ASTELLAS PHARMA UNSP.ADR in the global market cap rankings as of November 3, 2026. Also see YPHA total asset value for a full breakdown of the balance sheet.
Key companies related to ASTELLAS PHARMA UNSP.ADR by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #12 globally with a market cap of $1.06 Trillion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #20 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Johnson & Johnson (NYSE:JNJ): Ranked #29 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #42 globally with a market cap of $356.49 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #12 | Eli Lilly and Company | NYSE:LLY | $1.06 Trillion | $1410.99 |
| #20 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #29 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $270.56 |
| #42 | AbbVie Inc | NYSE:ABBV | $356.49 Billion | $288.84 |
Market Capitalization of ASTELLAS PHARMA UNSP.ADR (2020–2026)
Market capitalization of ASTELLAS PHARMA UNSP.ADR from 2020 to today. Between 2020 and today, ASTELLAS PHARMA UNSP.ADR's market cap moved from $22.79 Billion to $ 29.74 Billion, with a yearly change of 0.06%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €29.74 Billion | +27.93% |
| 2025 | €23.24 Billion | +23.33% |
| 2024 | €18.85 Billion | -13.11% |
| 2023 | €21.69 Billion | -22.17% |
| 2022 | €27.87 Billion | +3.08% |
| 2021 | €27.04 Billion | +18.62% |
| 2020 | €22.79 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of ASTELLAS PHARMA UNSP.ADR was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $19.55 Billion USD |
| MoneyControl | $19.55 Billion USD |
| MarketWatch | $19.55 Billion USD |
| marketcap.company | $19.55 Billion USD |
| Reuters | $19.55 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ASTELLAS PHARMA UNSP.ADR
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia (AML); VYLOY, a treatment for gastric cancer; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also provides VEOZAH, a treatment for vasomotor symptoms… Read more